Armistice Capital Reports 9.85% Stake in Treace Medical Concepts, Inc. (TMCI)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G/A with the SEC, reporting a significant stake in Treace Medical Concepts, Inc. (TMCI). The reporting persons disclosed beneficial ownership of 6,364,000 shares of common stock, representing 9.85% of the company's outstanding shares. This filing marks an increase from a previously reported 0% position, indicating a substantial new investment or position rebuilding. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Under the investment management agreement, Armistice Capital exercises shared voting and dispositive power over the securities. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own these shares. The filing certifies that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.